Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

The assay, developed by ValiRx subsidiary Inaphaea, uses patient-derived cells to predict sensitivity to drugs.

NEW YORK – ProteinQure said on Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...

NXC-201 is currently being evaluated in AL amyloidosis within a Phase Ib/II trial, but Immix plans to test it in other, undisclosed serious diseases.

The firm will use the funds to advance its mRNA therapies, including its lead candidate STX-001 for treating melanoma and triple-negative breast cancer.

The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.